- IN₹4.98bn
- IN₹6.00bn
- IN₹5.00bn
- 69
- 61
- 94
- 92
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.87 | ||
| EV to EBITDA | 9.17 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 56.18% | ||
| Return on Equity | n/a | ||
| Operating Margin | 9.24% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 3,913.74 | 3,674.55 | 3,925.18 | 5,111.86 | 4,996.47 | n/a | n/a | 5.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Wanbury Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical and related activities, including research. The Company operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. It has approximately 13 API products. It manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The Company's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).
Directors
- K. Chandran VCH (56)
- Vinod Verma CFO
- Jitendra Gandhi CCO
- Divakar Kaza NED
- Manisha Juvekar NID
- Binod Maharana NID
- N. Puri NID (75)
- Pallavi Shedge NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 11th, 1988
- Public Since
- February 24th, 1992
- No. of Shareholders
- 11,911
- No. of Employees
- 1,582
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 32,745,498
- Address
- 'B' Wing, 10th Floor, BSEL Techpark, NAVI MUMBAI, 400703
- Web
- http://www.wanbury.com/
- Phone
- +91 2267942222
- Contact
- Jitendra Gandhi
- Auditors
- V.Parekh & Associates
Upcoming Events for WANBURY
Q1 2025 Wanbury Ltd Earnings Release
Wanbury Ltd Annual Shareholders Meeting
Q2 2025 Wanbury Ltd Earnings Release
Similar to WANBURY
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Wanbury share price?
As of Today at 19:24 UTC, shares in Wanbury are trading at IN₹152.00. This share price information is delayed by 15 minutes.
How has the Wanbury share price performed this year?
Shares in Wanbury last closed at IN₹152.00 and the price had moved by +299.47% over the past 365 days. In terms of relative price strength the Wanbury share price has outperformed the S&P BSE 100 Index by +209.84% over the past year.
What are the analyst and broker recommendations for Wanbury?
There is no consensus recommendation for this security.
What is the Wanbury dividend yield?
Wanbury does not currently pay a dividend.
Does Wanbury pay a dividend?
Wanbury does not currently pay a dividend.
When does Wanbury next pay dividends?
Wanbury does not currently pay a dividend.
How do I buy Wanbury shares?
To buy shares in Wanbury you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Wanbury?
As of the previous close price of IN₹152.00, shares in Wanbury had a market capitalisation of IN₹4.98bn.
Where are Wanbury shares listed?
Here are the trading details for Wanbury:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: WANBURY
What kind of share is Wanbury?
Based on an overall assessment of its quality, value and momentum Wanbury is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Wanbury share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Wanbury share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wanbury. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +46.19%.
As of the last closing price of IN₹152.00, shares in Wanbury were trading +46.57% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Wanbury PE Ratio?
The Wanbury PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹152.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Wanbury?
Wanbury's management team is headed by:
- K. Chandran - VCH
- Vinod Verma - CFO
- Jitendra Gandhi - CCO
- Divakar Kaza - NED
- Manisha Juvekar - NID
- Binod Maharana - NID
- N. Puri - NID
- Pallavi Shedge - NID